Article
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2023
Helzer K T, Sharifi M N, Sperger J M, Shi Y, Annala M, Bootsma M L, Reese S R, Taylor A, Kaufmann K R, Krause H K, Schehr J L, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard M E, Rydzewski N R, Yu M, Harari P M, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley D A, Dehm S M, Armstrong A J, Beltran H, McKay R R, Feng F Y, O'Regan R, Wisinski K B, Emamekhoo H, Wyatt A W, Lang J M, Zhao S G
Abstract excerpt
BACKGROUND: The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment. More recently, cfDNA fragmentation patterns have emerged as a tool to infer epigenomic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.